Abstract:Rapid developments in Regenerative Medicine and Tissue Engineering has witnessed an increasing drive toward clinical translation of breakthrough technologies. However, the progression of promising preclinical data to achieve successful clinical market authorisation remains a bottleneck. One hurdle for progress to the clinic is the transition from small animal research to advanced preclinical studies in large animals to test safety and efficacy of products. Notwithstanding this, to draw meaningful and reliable conclusions from animal experiments it is critical that the species and disease model of choice is relevant to answer the research question as well as the clinical problem. Selecting the most appropriate animal model requires in-depth knowledge of specific species and breeds to ascertain the adequacy of the model and outcome measures that closely mirror the clinical situation. Traditional reductionist approaches in animal experiments, which often do not sufficiently reflect the studied disease, are still the norm and can result in a disconnect in outcomes observed between animal studies and clinical trials. To address these concerns a reconsideration in approach will be required. This should include a stepwise approach using in vitro and ex vivo experiments as well as in silico modeling to minimize the need for in vivo studies for screening and early development studies, followed by large animal models which more closely resemble human disease. Naturally occurring, or spontaneous diseases in large animals remain a largely untapped resource, and given the similarities in pathophysiology to humans they not only allow for studying new treatment strategies but also disease etiology and prevention. Naturally occurring disease models, particularly for longer lived large animal species, allow for studying disorders at an age when the disease is most prevalent. As these diseases are usually also a concern in the chosen veterinary species they would be beneficiaries of newly developed therapies. Improved awareness of the progress in animal models is mutually beneficial for animals, researchers, human and veterinary patients. In this overview we describe advantages and disadvantages of various animal models including domesticated and companion animals used in regenerative medicine and tissue engineering to provide an informed choice of disease-relevant animal models.

Animal Models for Cardiovascular Research

Small Mammalian Animal Models of Heart Disease.

Large Mammalian Animal Models of Heart Disease

Murine Models of Vascular Endothelial Injury: Techniques and Pathophysiology

Research('s) Sweet Hearts: Experimental Biomedical Models of Diabetic Cardiomyopathy

Non-Mouse Models of Atherosclerosis: Approaches to Exploring the Translational Potential of New Therapies

Animal Models for Heart Transplantation Focusing on the Pathological Conditions

Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do

Current Status and Limitations of Myocardial Infarction Large Animal Models in Cardiovascular Translational Research

Animal Models of Ischemic Heart Disease for in Vivo Cardiac MR Imaging Research

Animal Models of Cardiac Disease and Stem Cell Therapy.

Small and large animal models in cardiac contraction research: advantages and disadvantages

Advances in preclinical surgical therapy of cardiovascular diseases

Animal Models for the Atherosclerosis Research: a Review

Preclinical Models of Cardiac Disease: A Comprehensive Overview for Clinical Scientists

Application of Animal Models in Diabetic Cardiomyopathy

Animal models used in the research of nanoparticles for cardiovascular diseases

Animal models for cardiac arrhythmias.

Primate models for cardiovascular drug research and development.

Animal models of arrhythmia: classic electrophysiology to genetically modified large animals

Experimental Rodent Models of Cardiovascular Diseases